Navigation path

Additional tools



    Profile of registrant

F. Hoffmann-La Roche Ltd

Identification number in the register: 18940431725-51
Registration date: 20/05/2009 10:57:35

The information on this entity was last modified on: 22/04/2015 16:21:24
The date of the last annual update was: 22/04/2015 15:21:15
Next update due latest on: 22/04/2016

    Registrant : Organisation or self-employed individual

F. Hoffmann-La Roche Ltd

Roche

Corporation

    Section of registration

II - In-house lobbyists and trade/business/professional associations

Companies & groups

    Contact details

Grenzacherstrasse, 124
Basel 4070
SWITZERLAND

(+41)61 688 11 11

    Person with legal responsibility

Mr  Severin Schwan

CEO

    Person in charge of EU relations

Ms  Nathalie Stieger

Head of Government Affairs

    Goals / remit

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014 the Roche Group employed over 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

global

    Specific activities covered by the Register

- Interactions (direct contacts) with EU Institutions relating to legislation and implementation of EU regulation at national level: e.g. IVD / Medical Devices Regulation, Data Protection Regulation, Clinical Trials Regulation, Horizon 2020/IMI, Pharmaceuticals in the Environment, Falsified Medicines Directive
- Provide input to EU Institutions open consultations, including participation in events sponsored by EU Institutions
- Improve patient safety and strengthen disease prevention in Europe
- Provide coverage and reimbursement that reward innovation
- Increase Europe's competitiveness as a location for Research and Development investment
- Pharmaceuticals, Diagnostics, Diabetes Care, Intellectual Property, Trade


 

No

No

No

No

No

    Number of persons involved in the activities described in the box above

75%: 3   50%: 3   25%: 2

8

4.2

The current calculation of the number of persons involved relies on a new calculation method following the Guidelines of the Joint Secretariat of the Transparency Register and can therefore NOT be compared to the entry of the previous year.
This new estimate follows and is consistent with the recommendations of the Guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

    Persons accredited for access to European Parliament premises

First name Surname Start Date End Date
Christiane LANDSBERG 29/07/2015 28/07/2016
Nathalie STIEGER 21/06/2015 18/06/2016

    Fields of interest

  • Budget
  • Competition
  • Consumer Affairs
  • Development
  • Economic and Financial Affairs
  • Enterprise
  • Environment
  • External Relations
  • Internal Market
  • Justice and Fundamental Rights
  • Public Health
  • Research and Technology
  • Trade

    Membership and affiliation

Roche is a member of EFPIA, EDMA and national pharmaceutical and diagnostics associations, EBE, EAPM, Kangaroo Group, AMISA2.

    Financial data

01/2014  -  12/2014

1,000,000 € - 1,249,999 €

No funding received from the EU institutions during the last closed financial year.

The current estimate of cost relies on a new calculation method following the Guidelines of the Joint Secretariat of the Transparency Register and can therefore NOT be compared to the entry of the previous year.
The cost estimate includes employee activities (calculated as salary cost per FTE on activities within scope as well as pro-rata travel-related costs/office expenses), activities of external professional consultancies, as well as membership fees and sponsoring (to associations etc.).
This new estimate follows and is consistent with the recommendations of the Guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Roche would like to indicate that all entries have been made in line with the greatest possible transparency and are periodically being updated, as soon as e.g. the Joint Secretariat issues new guidelines introducing additional requirements.

    Code of conduct

By its registration the organisation has signed the Transparency Register Code of Conduct.

The organisation has also declared to be bound to the following other Code:
Roche Group Code of Conduct, Codes of Conduct of listed associations